449 related articles for article (PubMed ID: 29178871)
1. Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis.
Miravitlles M; Urrutia G; Mathioudakis AG; Ancochea J
Respir Res; 2017 Nov; 18(1):196. PubMed ID: 29178871
[TBL] [Abstract][Full Text] [Related]
2. Differences in Real-World Health and Economic Outcomes Among Patients with COPD Treated with Combination Tiotropium/Olodaterol Versus Triple Therapy.
Palli SR; Frazer M; DuCharme M; Buikema AR; Anderson AJ; Franchino-Elder J
J Manag Care Spec Pharm; 2020 Oct; 26(10):1363-1374. PubMed ID: 32678719
[TBL] [Abstract][Full Text] [Related]
3. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.
Rodrigo GJ; Price D; Anzueto A; Singh D; Altman P; Bader G; Patalano F; Fogel R; Kostikas K
Int J Chron Obstruct Pulmon Dis; 2017; 12():907-922. PubMed ID: 28360514
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol.
Moretz C; Bengtson LG; Sharpsten L; Koep E; Le L; Tong J; Stanford RH; Hahn B; Ray R
Int J Chron Obstruct Pulmon Dis; 2019; 14():2047-2060. PubMed ID: 31564852
[TBL] [Abstract][Full Text] [Related]
5. Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.
Feldman GJ; Sousa AR; Lipson DA; Tombs L; Barnes N; Riley JH; Patel S; Naya I; Compton C; Alcázar Navarrete B
Adv Ther; 2017 Nov; 34(11):2518-2533. PubMed ID: 29094315
[TBL] [Abstract][Full Text] [Related]
6. The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects.
Derom E; Brusselle GG; Joos GF
Ther Adv Respir Dis; 2019; 13():1753466619843426. PubMed ID: 31002020
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Tiotropium/Olodaterol Compared with Tiotropium as a First-Line Maintenance Treatment in Patients with COPD Who Are Naïve to LAMA, LABA and ICS: Pooled Analysis of Four Clinical Trials.
Buhl R; de la Hoz A; Xue W; Singh D; Ferguson GT
Adv Ther; 2020 Oct; 37(10):4175-4189. PubMed ID: 32671684
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies.
ZuWallack R; Allen L; Hernandez G; Ting N; Abrahams R
Int J Chron Obstruct Pulmon Dis; 2014; 9():1133-44. PubMed ID: 25342898
[TBL] [Abstract][Full Text] [Related]
9. Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease.
Ramadan WH; Kabbara WK; El Khoury GM; Al Assir SA
Int J Chron Obstruct Pulmon Dis; 2015; 10():2347-56. PubMed ID: 26586940
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease.
Muraki M; Kunita Y; Shirahase K; Yamazaki R; Hanada S; Sawaguchi H; Tohda Y
BMC Pulm Med; 2021 Jan; 21(1):26. PubMed ID: 33441146
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of tiotropium-olodaterol fixed-dose combination in COPD.
Derom E; Brusselle GG; Joos GF
Int J Chron Obstruct Pulmon Dis; 2016; 11():3163-3177. PubMed ID: 28008243
[TBL] [Abstract][Full Text] [Related]
12. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life.
Singh D; Ferguson GT; Bolitschek J; Grönke L; Hallmann C; Bennett N; Abrahams R; Schmidt O; Bjermer L
Respir Med; 2015 Oct; 109(10):1312-9. PubMed ID: 26320402
[TBL] [Abstract][Full Text] [Related]
13. Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO
Buhl R; Singh D; de la Hoz A; Xue W; Ferguson GT
Adv Ther; 2020 Aug; 37(8):3485-3499. PubMed ID: 32462607
[TBL] [Abstract][Full Text] [Related]
14. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
Farne HA; Cates CJ
Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
[TBL] [Abstract][Full Text] [Related]
15. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.
Maqsood U; Ho TN; Palmer K; Eccles FJ; Munavvar M; Wang R; Crossingham I; Evans DJ
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012930. PubMed ID: 30839102
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies.
Ichinose M; Taniguchi H; Takizawa A; Grönke L; Loaiza L; Voß F; Zhao Y; Fukuchi Y
Int J Chron Obstruct Pulmon Dis; 2016; 11():2017-27. PubMed ID: 27621608
[TBL] [Abstract][Full Text] [Related]
17. Systematic literature review and meta-analysis of US-approved LAMA/LABA therapies versus tiotropium in moderate-to-severe COPD.
Han MK; Ray R; Foo J; Morel C; Hahn B
NPJ Prim Care Respir Med; 2018 Aug; 28(1):32. PubMed ID: 30150639
[TBL] [Abstract][Full Text] [Related]
18. Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study.
Kerwin EM; Kalberg CJ; Galkin DV; Zhu CQ; Church A; Riley JH; Fahy WA
Int J Chron Obstruct Pulmon Dis; 2017; 12():745-755. PubMed ID: 28280319
[TBL] [Abstract][Full Text] [Related]
19. COPD Maintenance Therapy with Tiotropium/Olodaterol Compared with Tiotropium: An Analysis in the Absence of Additional ICS Therapy.
Calverley PMA; Hoz A; Xue W; Ferguson GT; Miravitlles M
COPD; 2020 Oct; 17(5):477-484. PubMed ID: 32928003
[TBL] [Abstract][Full Text] [Related]
20. [LAMA/LABA fixed dose combination for treatment of COPD].
Kuwahira I
Nihon Rinsho; 2016 May; 74(5):820-6. PubMed ID: 27254953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]